No Data
No Data
Chordia --- won the Innovation Award 2024.2Q sponsored by Mizuho Bank.
Chordia Therapeutics <190A> announced that it has been selected as a winning company in the 'Mizuho Innovation Award 2024.2Q', in which Mizuho Bank, a group company of Mizuho Financial Group <8411>, awards promising innovative companies every quarter. As a recipient of the 'Mizuho Innovation Award', the company will be provided with business opportunities with large corporations from Mizuho Bank.
Sumitomo Riko, Shionogi, etc. (additional) rating.
Upgrade-Power Code | Stock Name | Securities Company | Previous | After changing | ------ | --------------- | ------------- | -------------- | -------------- | <2212> | Yamazaki Bread | GS | "Hold" | "Buy" | <4293> | Septeni HD | MSMUFG | "UnderW" | "Iko"
I-ne, Ono Pharmaceutical Industries, etc. (added) Rating.
Upgrade - Bullish Code | Stock Name | Securities Company | Conventional | Revised | ------ | ------------------- | ----------- | ------- | ------- | <1911> | Sumitomo Forestry Co., Ltd. | SMBC Nikko | "2" | "1" | Target share price change code | Stock Name | Securities Company | Conventional | Revised | ------ | ------------------- |
Ono Pharmaceutical Advances Governance and Diversity
Emerging Market Stock Digest: Rigua fell sharply, while PRISM Bio hit the limit up.
<7090> Rigua 1980 -410 fell sharply. Although it reached the limit up in the morning, it turned negative on a comparison with the previous day's closing price due to profit-taking sales later. Rigua announced that its new product "SLEEPINSTANT", an IFMC. (Integrated Functional Mineral Crystal) product developed by the company, has been introduced into all rooms (total of 784 beds) of the Kansai Airport Washington Hotel (Izumisano City, Osaka Prefecture), and investment funds were flowing in. IFMC. is a product that can be installed close to the body.
PRISM Bio's stock has hit the limit up, with strong buying even after its debut on the stock market. It has signed out-licensing agreements with Eisai and others.
With a limit up, having newly listed the previous day, and despite debuting at a price above the public offering price (450 yen) at 489 yen, there is still a strong buying surge. They are engaged in pharmaceutical research and development, and in addition to licensing agreements with Eisai <4523> and Obara Yakuhin Kogyo (Chuo-ku, Tokyo) for their proprietary development business, they also have partnerships with Ono Yakuhin Kogyo <4528> and others for their joint development business.
No Data